Adrenaline Pharmacology
Clinical Particulars
Pharmacodynamics
Adrenaline (Epinephrine) is a sympathomimetic drug. It causes an adrenergic receptive mechanism on effector cells and mimics all actions of the sympathetic nervous system except those on the facial arteries and sweat glands. Epinephrine also alleviates pruritus, urticaria, and angioedema. Adrenaline may help relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxing effects on the smooth muscle of the stomach, intestine, uterus, and urinary bladder (Farzam et al., 2024; Oyebola, 2011). During reperfusion, adrenaline may counteract cerebral vasoconstriction (Kondo et al., 2022).
Mechanism of Action
Adrenaline may demonstrate valuable short-term benefits during CPCR, but it is also arrhythmogenic and increases the heart's workload. High doses in many species are considered harmful during CPCR (Rozanski et al., 2012) and have been shown to reduce body tissue oxygen levels in rabbits (Towell et al., 1981). Other catecholamines, such as dopamine and dobutamine, are generally preferred in major pet species if sustained Adrenaline use is anticipated (DeWitt et al., 2016). Specific receptor effects include:
⍺-1 Sympathomimetic Activity: Smooth muscle contraction, mydriasis
⍺-2 Sympathomimetic Activity: Mixed smooth muscle effects
β-1 Sympathomimetic Activity: Increased cardiac chronotropic and inotropic effects (increased heart rate, myocardial contractility, and renin release)
β-2 Sympathomimetic Activity: Bronchodilation
Clinical Applications
There are a variety of potential applications; Adrenaline (Epinephrine) demonstrates a broad spectrum of pharmacologic activity.
Primary Systemic Applications
Resuscitation associated with anaesthesia-induced cardiac arrest: ⍺-1 and β-1 activity is beneficial during CPR.
Resuscitation outside general anaesthesia: ⍺-1 and β-1 activity is beneficial during CPR.
Anaphylaxis: ⍺-adrenergic activity reduces vasodilation and increases vascular permeability during anaphylaxis.
Bronchospasm: β-2 activity results in bronchodilator.
Secondary Systemic Applications
In human medicine, adrenaline is used for
Type I allergic reactions, including anaphylaxis, hypotension associated with septic shock,
Syncope;
Urticaria,
Local Applications
Hemostasis,
Rhinitis, acute sinusitis
Angioneurotic oedema
Open-angle Glaucoma
Uterine Relaxation
Prolongation of action of local anaesthetics
Mydriasis during intraocular surgery
(PubChem, 2024; Farzam et al., 2024).
Pharmacokinetics
Biotransformation
Mixed sites: Epinephrine is rapidly inactivated in the body mostly by the enzymes COMT (catechol-O-methyltransferase) and MAO (monoamine oxidase). The liver is a major site, although the process also occurs in many other tissues.
Elimination
Urine: Epinephrine is rapidly inactivated mainly by enzymic transformation to metanephrine or normetanephrine, either of which is then conjugated and excreted in the urine in the form of both sulfates and glucuronides.
Precautions
Adverse Effects
Various adverse effects are possible during CPCR, but their significance is limited as they depend on achieving ROSC and are of no consequence if the patient dies.
CPCR systemic adverse effects: Tremors, excitability, vomiting, hypertension, tachycardia, arrhythmias, pulmonary oedema, hyperglycemia, dysphoric behaviour changes (e.g., anxiety, excitability), and lactic acidosis have been described in humans.
Adverse effects at the injection site: Repeated injections may result in tissue necrosis and sloughing at any injection site (SPC Data).
Contraindications
DNR agreements: No absolute contraindications to epinephrine use in life-threatening situations are identified unless there is a preexisting legal request or agreement not to resuscitate.
Reproductive Safety
Pregnancy: Adverse effects upon pregnancy are of limited significance during life-threatening situations. A teratogenic effect has been demonstrated in animal experiments (SPC Data).
Lactation: Adverse effects upon suckling offspring are of limited significance during life-threatening situations. Adrenaline is distributed into breast milk.
Male Fertility: No data on subsequent post-CPCR fertility (SPC Data).
Female Fertility: No data on subsequent post-CPCR fertility (SPC Data).
Interactions
Sympathomimetic Agents: Physiological results are unpredictable, and additive effects may occur (SPC Data).
Adrenergic Agents: Diphenhydramine, chlorpheniramine, and levothyroxine may potentiate the effects of adrenaline (epinephrine) (SPC Data).
Antagonist Agents: Nitrates, α-blocking agents and diuretics may abolish or reduce the pressure effects of adrenaline (epinephrine) (SPC Data).
β-blockers: Concomitant use may potentiate hypertension and antagonise the bronchodilatory and cardiostimulatory benefits (SPC Data).
Oxytocin: Concurrent use may result in postpartum hypertension (SPC Data).
Proarrhythmic Agents: Concurrent use of proarrhythmic agents (e.g., halothane, digoxin) may sensitise the myocardium to arrhythmias (SPC Data).
Availability
Formulations
Adrenaline (epinephrine) is available in injectable formulations as 0.1 mg/mL (1:10,000) and 1 mg/mL (1:1000) solutions. 1: 10,000 is the most often used IV, and the 1: 1000 solution is used IM or SQ. Ampules for people are designed to deliver 1 mg/person (approximately 14 mcg/kg).
Our evidence review includes a range of UK SPCs (EMC, 2024a, 2024b, 2024c, 2024d, 2024e).
Some authors advocate diluting human ER adrenaline solutions 1:10 with saline or crystalloids to limit the possibility of excessive dosing in minor pet species.
Identifiers
Systematic Name: IUPAC Name - 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol (PubChem, 2024).
Formula: C9H13NO3 (PubChem, 2024).
Pharmacotherapeutic group:
ATC Code(s): A01AD01; B02BC09; C01CA24; R01AA14; R03AA01; R03AA01; S01EA01; R03AK01; S01EA51 (“Adrenaline (Epinephrine) WHOCC - ATC/DDD Index,” 2024)
ATC Vet Code: -QC01CA
Evidence-Base
Terms and Conditions
Although our services are designed to provide accurate and authoritative information on the subject matter covered, VetConsensus collaborators (all members, employees, collaborators, consultants, sponsors and partners) make no representations and give no warranties, express or implied, about the accuracy or completeness of information, or associated recommendations.
-
We are not advising clinicians about specific patients under active treatment.
-
We are not endorsing any medicine, merchandise, protocol or technique by making available information and giving recommendations.
The information provided here is not a substitute for the exercise of professional judgment, for which an attending clinician is always responsible.
This database and its network of related websites are protected by copyright law. All rights are reserved.
-
Specific content, such as articles, photos, and images, is subject to the copyright of its respective owners. All rights reserved.
-
Unauthorised distribution, transmission or publication is strictly prohibited.
-
Materials obtained through our websites belong to their respective owners and are protected by national and international intellectual property laws, conventions, and treaties. Single copies may be used for personal, non-commercial purposes only.
All other rights are reserved, and commercial uses, including publication, retransmission, broadcast, posting to newsgroups, mail lists or electronic bulletin boards, circulation, selling, reproduction or redistribution in any medium, are prohibited, except with the prior written approval of the copyright owner. The Veterinary Publishing Company may take appropriate legal action if these rights are infringed.